Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Rhytides: early-phase trial registry

A small indexed set (6 trials) with no open enrollment listed right now.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count

Rhytides: 6 US clinical trials tracked, none currently recruiting.

Rhytides is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Lupo Center for Aesthetic and General Dermatology, running 1 of these trials.

Enrollment posture brief

Registry condition rhytides

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #2866 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Rhytides (this)0%
Open-enrollment share among volume-matched conditions near Rhytides

Rhytides has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rhytides on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rhytides is recruiting below its size-band peers.

    0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Rhytides research.

    Lupo Center for Aesthetic and General Dermatology accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Rhytides trials plan to enrol fewer than 100 people.

    Median target enrolment is 19 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Rhytides research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Rhytides records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

vehicle Combination
1 trials
5% red maple leaf extract Combination
1 trials
1% red maple leaf extract in cream base Combination
1 trials
PrabotulinumtoxinA-Xvfs Drug
1 trials
Venus Viva Device
1 trials
Clay mask Other
1 trials
ellacor® Micro-Coring procedure Device
1 trials
Restylane Refyne Device
1 trials

US sites by state

Facility locations filed on Rhytides trials. A trial with sites in several states counts in each.

California 2 trials
Texas 1 trials
New York 1 trials
Louisiana 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rhytides page

6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rhytides condition card totals 6 registered trials; most-linked intervention vehicle; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.